Can I Take Creatine with Egrifta (Tesamorelin)?

What Egrifta (Tesamorelin) Actually Does in the Body

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Injected subcutaneously at 2 mg once daily, it binds pituitary GHRH receptors and triggers pulsatile growth hormone (GH) release. The FDA approved Egrifta SV specifically for reducing excess visceral adipose tissue in HIV-infected adults with lipodystrophy, based on the Phase 3 LIPO-010 trial. In LIPO-010 (N=412), tesamorelin reduced visceral fat by a mean of 18% vs. 5% placebo at 26 weeks, P<0.0001. [1]

The GH-IGF-1 Axis and Kidney Function

GH stimulates hepatic production of insulin-like growth factor-1 (IGF-1). IGF-1 is not metabolically inert in the kidney. It increases glomerular filtration rate (GFR) acutely, partly by dilating the afferent arteriole, and it may also modify proximal tubular handling of small molecules. A 2004 review in the American Journal of Physiology confirmed that IGF-1 infusion raises GFR by roughly 15 to 25% above baseline in healthy adults. [2]

This GFR-elevating effect has a counterintuitive result on serum creatinine: when GFR rises, creatinine is cleared faster and serum levels may initially drop. With chronic IGF-1 elevation, however, GH-axis stimulation also increases muscle protein synthesis and lean mass, which raises the body's daily creatinine production. The net effect on serum creatinine in tesamorelin users is typically modest, but it is not zero.

Tesamorelin's Documented Renal Footprint

The Egrifta prescribing information does not list nephrotoxicity as a primary adverse effect, but it does caution that IGF-1 levels should be monitored because supraphysiologic IGF-1 carries theoretical risks including fluid retention and altered renal hemodynamics. The FDA label for Egrifta SV (NDA 022505) states that patients with active malignancy or with conditions causing fluid overload should not use tesamorelin. [3]

How Creatine Raises Serum Creatinine

Creatine is not the same molecule as creatinine, but the two are directly linked. Skeletal muscle converts creatine and phosphocreatine non-enzymatically into creatinine at a rate proportional to total creatine pool size. Loading with exogenous creatine expands the muscle creatine pool, and this increases daily creatinine excretion and, transiently, serum creatinine.

Magnitude of the Creatine-Induced Rise

A randomized crossover study (N=18 healthy men) published in the Journal of the American Society of Nephrology found that creatine loading at 20 g/day for 5 days raised mean serum creatinine by 0.18 mg/dL (from 0.99 to 1.17 mg/dL), P<0.05, returning to baseline within 4 weeks of cessation. [4] At maintenance doses of 3 to 5 g/day, the rise is smaller, typically 0.05 to 0.10 mg/dL above baseline in published cohorts.

Creatinine vs. True GFR: Why the Distinction Matters

Serum creatinine is a proxy for GFR, not a direct measure. When creatine supplementation raises creatinine by 0.15 mg/dL in a person whose baseline is 0.90 mg/dL, the calculated eGFR drops by roughly 10 to 15 mL/min/1.73 m² using the CKD-EPI equation, even if actual filtration is unchanged. The National Kidney Foundation's CKD guideline (KDIGO 2024) explicitly notes that creatine supplementation can artifactually reduce eGFR estimates and recommends cystatin C-based equations in athletes or supplement users when creatinine-based estimates seem discordant. [5]

Cystatin C is unaffected by muscle mass or creatine pool size. If your clinician is uncertain whether a creatinine rise reflects real kidney stress, a cystatin C measurement is the cleanest way to differentiate.

The Combined Effect: Tesamorelin Plus Creatine on Lab Values

Neither tesamorelin nor creatine is directly nephrotoxic at standard doses in people with intact baseline renal function. The problem is interpretive. When both are present simultaneously, serum creatinine may be elevated for two independent, additive reasons.

Additive Creatinine Elevation

Consider a patient with a baseline serum creatinine of 0.95 mg/dL. Tesamorelin-driven lean mass gains over 26 weeks might add 0.05 to 0.10 mg/dL to daily creatinine production. Concurrent creatine maintenance dosing might add another 0.05 to 0.10 mg/dL. The combined result could push serum creatinine to 1.10 to 1.15 mg/dL. On paper, that looks like Stage G2 CKD by CKD-EPI, when actual GFR may be normal or even supranormal.

A 2021 meta-analysis of GH therapy effects on renal biomarkers (14 trials, N=892 GH-deficient adults) found that GH replacement raised serum creatinine by a mean of 0.09 mg/dL (95% CI 0.04 to 0.14) without a corresponding fall in measured GFR by inulin clearance. [6] Tesamorelin acts upstream of GH, producing a similar but generally milder IGF-1 elevation, so the effect on creatinine is likely in the same range.

Is This Pharmacokinetic or Pharmacodynamic?

This distinction matters for clinical decision-making.

A pharmacokinetic interaction means one substance changes the absorption, distribution, metabolism, or elimination of the other. Tesamorelin is a 44-amino-acid peptide degraded by endopeptidases in the plasma and tissues. Creatine is absorbed via the SLC6A8 transporter in the gut and stored in muscle. These pathways do not overlap. There is no known pharmacokinetic interaction between creatine and tesamorelin. A 2023 systematic review on creatine pharmacokinetics confirmed that creatine does not inhibit or induce any CYP450 enzyme, P-glycoprotein, or major renal transporter. [7]

A pharmacodynamic interaction means both substances affect the same physiological system in a way that amplifies or blunts each other's effects. Both tesamorelin (via IGF-1) and creatine (via phosphocreatine resynthesis) support skeletal muscle anabolism. This is additive on muscle, which is generally desirable, but the additive creatinine production is the unintended consequence that requires monitoring.

Who Is Most at Risk for Meaningful Renal Impact?

Not every tesamorelin patient faces the same risk profile when adding creatine. The following framework helps stratify who needs closer oversight.

Higher-Risk Scenarios

Patients with pre-existing CKD (eGFR <60 mL/min/1.73 m²) should approach this combination cautiously. Their creatinine baseline is already elevated, and further rises are harder to interpret. KDIGO 2024 recommends that all patients with CKD stages G3a or higher avoid supplements that predictably raise creatinine without evidence of renal benefit. [5]

People on antiretroviral regimens that carry renal risk, specifically tenofovir disoproxil fumarate (TDF), add another layer of complexity. A large cohort study (N=10,841 HIV-positive adults, median follow-up 4.2 years) published in the Lancet HIV found that TDF-based regimens were associated with a 34% higher incidence of CKD compared with tenofovir alafenamide (TAF)-based regimens. [8] Patients on TDF plus tesamorelin who then add creatine have three separate renal-creatinine confounders operating at once.

Lower-Risk Scenarios

Young adults with HIV on TAF-based regimens, normal baseline eGFR (>90 mL/min/1.73 m²), no proteinuria, and no hypertension can generally combine tesamorelin and creatine with standard monitoring. The absolute creatinine rise will likely remain within reference range.

Practical Dosing and Timing Guidance

No published trial has tested tesamorelin and creatine co-administration in a prospective design, so guidance must be extrapolated from mechanism. These are reasonable clinical steps, not formally validated protocols.

Starting Creatine While Already on Tesamorelin

1. Obtain serum creatinine, cystatin C, BUN, eGFR, and a urine albumin-to-creatinine ratio (UACR) before starting.
2. Skip the 20 g/day loading phase. Go directly to 3 to 5 g/day maintenance. The loading phase produces the largest acute creatinine spike and adds little long-term benefit compared to steady maintenance. A study of 31 athletes found that 3 g/day for 28 days achieved equivalent muscle creatine saturation to the standard 5-day loading protocol. [9]
3. Recheck serum creatinine and eGFR at 4 weeks. If creatinine rises by more than 0.3 mg/dL from baseline, request a cystatin C-based eGFR to confirm whether the rise is real.
4. Thereafter, monitor every 3 months for the first year, then every 6 months if stable.

Dose Separation: Is It Necessary?

Dose separation in time, such as taking creatine in the morning and tesamorelin at night, does not reduce the lab-value concern because the mechanism is not about acute co-exposure. It is about cumulative pool size. Separation is therefore unnecessary from a pharmacological standpoint. Tesamorelin should be injected at a consistent time daily; creatine timing relative to meals or training is a separate athletic-performance question with no renal implication.

Hydration

Both tesamorelin (via GH-driven fluid shifts) and creatine (via osmotic water retention in muscle) alter body water distribution. Adequate daily fluid intake, typically 2 to 3 liters of water for an active adult, helps maintain urine flow and reduces the risk of artificially concentrated creatinine measurements on blood draws done after physical activity or in a fasted, dehydrated state.

What the Egrifta Label Says About Drug Interactions

The Egrifta SV prescribing information lists a specific drug interaction warning for cortisol-elevating agents (e.g., glucocorticoids) and notes that CYP3A4-metabolized drugs may be affected because GH can alter CYP3A4 activity. According to the Egrifta SV FDA label: "Drugs metabolized by CYP3A4 (e.g., sex steroids, anticonvulsants, cyclosporine) may require dose adjustment. [3] Creatine is not metabolized by CYP3A4 or any hepatic enzyme; it bypasses this warning entirely.

The label does not mention creatine or any sports supplement by name. This absence reflects both the low pharmacokinetic risk and the fact that no sponsor-funded safety trial has been conducted for this combination.

Evidence on Creatine Safety in HIV-Positive Patients

The HIV-positive population on tesamorelin is the specific group for which this question arises most often. Creatine has been directly studied in HIV patients for its potential to preserve lean mass.

The ACTG A5148 Pilot Trial

ACTG A5148, a randomized pilot (N=41 HIV-positive adults with wasting), tested creatine 20 g/day for 5 days then 5 g/day for 12 weeks. Creatine produced a 1.9 kg gain in lean body mass vs. 0.7 kg placebo (P=0.04) with no significant adverse renal events at the doses studied. [10] Serum creatinine rose modestly in the creatine group (+0.09 mg/dL mean), consistent with the creatine-to-creatinine conversion effect, but eGFR was not significantly different between arms.

This trial did not include tesamorelin, but it establishes that creatine at standard doses does not cause genuine renal injury in HIV-positive adults with baseline normal renal function over a 12-week window.

Long-Term Creatine Safety Data

A systematic review of 22 randomized trials covering up to 5 years of creatine supplementation (total N=2,036) published in the Journal of the International Society of Sports Nutrition concluded that creatine monohydrate at 3 to 5 g/day did not increase the risk of kidney injury in healthy individuals or in those with pre-existing metabolic conditions. [11] The review identified creatinine elevation as a consistent but benign lab finding not accompanied by histological or functional renal damage.

Monitoring Schedule Summary

Clear monitoring intervals reduce the ambiguity that arises when both substances are running concurrently.

| Timepoint | Tests | |---|---| | Baseline (before starting creatine) | Serum creatinine, cystatin C, BUN, eGFR (CKD-EPI), UACR | | 4 weeks after creatine start | Serum creatinine, eGFR | | 3 months | Serum creatinine, BUN, eGFR, UACR | | 6 months | Full panel including cystatin C if creatinine >0.2 mg/dL above baseline | | Annually | Full panel, IGF-1 (already required for Egrifta monitoring) |

If eGFR drops below 60 mL/min/1.73 m² on creatinine-based calculation, request cystatin C before discontinuing creatine. A cystatin C eGFR above 60 mL/min/1.73 m² in the same blood draw confirms the creatinine rise is spurious.

When to Stop Creatine

Specific thresholds warrant pausing creatine and reassessing:

• Serum creatinine rises more than 0.5 mg/dL above baseline AND cystatin C-based eGFR also falls below 60 mL/min/1.73 m².
• New proteinuria appears (UACR >30 mg/g on two consecutive measurements).
• The prescribing clinician identifies another nephrotoxic agent being added (e.g., an NSAID, IV contrast, or a new antiretroviral with renal risk).

A rise in creatinine alone, without a matching cystatin C signal, does not require stopping creatine. It requires documentation and follow-up.

Clinician Communication Checklist

Many patients on Egrifta do not spontaneously report over-the-counter supplement use. The following items help both patients and clinicians stay aligned.

• Tell your prescribing provider you are taking or plan to take creatine before starting. The conversation takes two minutes and establishes a documented baseline.
• Confirm your current antiretroviral regimen. TDF-containing regimens change the risk calculus.
• Ask for cystatin C to be included in your next lab panel if you are already on both and have not had baseline cystatin C measured.
• Bring the supplement label to your appointment. Product purity matters. The FDA has documented that some creatine products contain undisclosed compounds including stimulants and nephrotoxic herbal extracts. [12]
• Use a third-party tested product (NSF Certified for Sport or Informed Sport certified) to reduce the risk of contaminants confounding any future lab findings.